Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Pharmacokinetic Study of Fixed-Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide Taken as 5 Days Per Week (5/7) Versus Continuous Therapy as 7 Days Per Week (7/7) in HIV-1-Infected Participants Who Are Virally Suppressed

NCT06773754 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT06773754
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06773754 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Pharmacokinetic Study of Fixed-Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide Taken as 5 Days Per Week (5/7) Versus Continuous Therapy as 7 Days Per Week (7/7) in HIV-1-Infected Participants Who Are Virally Suppressed
Lead sponsor
National Taiwan University Hospital
Phase
Not applicable
Overall status
Active, not recruiting
Start date
June 14, 2022
Completion date
December 31, 2025
Enrollment
60 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

virally suppressed people with hiv